Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into ...

US$6.60 loss per share (further deteriorated from US$4.58 loss in 1H 2024). AI is about to change healthcare. These 20 stocks ...

RADIANT study with vormatrigine in focal onset seizure (FOS) patients over eight weeks demonstrated 56.3% median reduction in ...

Praxis Precision Medicines (PRAX) stock gains on mid-stage trial data for its anti-seizure therapy vormatrigine. Read more ...

Praxis Precision Medicines' vormatrigine shows promise in epilepsy with 56.3% seizure reduction. Click here to find out why I ...

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) stock experienced a volatile trading session on Monday, after the company ...

Praxis Precision Medicine PRAX -4.09% Get Free Report will release its quarterly earnings report on Monday, 2025-08-04. Here's a brief overview for investors ahead of the announcement. Analysts ...

Praxis Precision Medicines, Inc. (($PRAX)) has held its Q2 earnings call. Read on for the main highlights of the call. Praxis Precision Medicines, ...

Pomerantz LLP is investigating claims on behalf of investors of  Praxis Precision Medicines, Inc. ("Praxis" or the "Company") (NASDAQ: PRAX). Such investors are advised to contact Danielle Peyton at ...

Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX) soared 27% on Monday after the company released encouraging top-line ...

Investing.com -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX) stock surged 27% on Monday after the company announced positive topline results from its Phase 2 RADIANT study evaluating vormatrigine ...

Praxis Precision Medicines has reported a 56.3% median reduction in seizure frequency from baseline in a midphase trial, encouraging the biotech to push ahead with phase 2/3 plans despite almost a ...